News

The acquisition was decided on the back of The Medicines Company’s inclisiran trials.

The results mark the first time in a decade that a treatment has improved overall survival for the indication.

Currently, a significant number of patients deemed “at risk” are implanted with implantable cardioverter-defibrillators that are never needed, which can be severely detrimental to their overall health.

The approval was based on positive results from the interim analyses of two Phase III clinical trials, ELEVATE-TN and ASCEND.

The Party’s manifesto puts emphasis on investing in the NHS and increasing expenditure across the health sector, but the BMA says the promises are not enough.

The specialist HIV company has signed an exclusive licensing agreement for an investigational broadly neutralising antibody (bNAb) – N6LS.

The project aims to move away from traditional printed leaflets, and towards digital systems and immersive content, including some virtual reality content.

Health and social care firms invested the second highest amount in cyber security overall in 2018-19.

New NHS statistics show an increase in uptake for the first time in five years.

Back in February, the purchase hit a significant obstacle after BMS’ largest institutional shareholder – Wellington Management – said it did not back the deal.

The company was initially formed in 2017 off the back of research by Professor Jason Carroll, whose scientific insights have led to a new approach to target FOXA1 driven cancer.

The MSD blockbuster has been approved as monotherapy or as part of a chemotherapy combination.

GSK’s formulation of the drug, Zantac, was recalled in the USA last month after the FDA found “unacceptable” levels of carcinogen in the medicine.

96.7% of men in the relugolix trial achieved sustained testosterone suppression to castrate levels.